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INTRODUCTION
In 1862, the German chemist Adolph Strecker isolated a strongly alkaline nitrogen-containing base and named it choline, which linked an earlier discovery by Theodore Gobley of lécithine, now known to have been phosphatidylcholine (PC) (1) . Choline is recognized as an essential nutrient that has critical functions as the precursor to the membrane phospholipid, PC, the precursor for the neurotransmitter, acetylcholine, as well as a methyl group donor (2) . In the liver, PC is the major membrane phospholipid and is mainly synthesized by the CDP-choline (Kennedy) pathway and supplemented via the methylation of phosphatidylethanolamine (PE) via the PE Nmethyltransferase (PEMT) pathway (3) .
In the 1930s, Best and Huntsman first documented that choline deficiency was the root cause for the development of fatty liver in animals placed on an insufficient diet (4) (5) (6) , results later corroborated in humans (7) . Moreover, the importance of PC availability has become apparent using genetic mouse models. Targeted deletion of the first intracellular step of the CDP-choline pathway, choline kinase alpha (CHKα) and the rate-limiting step, phosphocholine cytidylyltransferase α (CCTα, encoded by the Pcyt1a gene), are lethal in utero (8, 9) . Liver specific Pcyt1a-deficient mice had lower PC synthesis and higher liver triacylglycerol, in spite of a 2-fold increase in PEMT activity (10) . Finally, although Pemt-deficient mice fed a normal diet have minimal disruptions to hepatic phospholipid metabolism, when fed a choline deficient diet, the lack of CDP-choline pathway flux results in complete liver failure within 3 days (11) .
Choline is a positively charged quaternary amine and requires a transport through cellular membranes. While the choline transporter SLC5A7 is a neuronal-specific, high-affinity choline transporter, in non-neuronal tissue, low-and intermediate-affinity transporters have been described (12) . Organic cation transporters (SLC22A1-3) uptake a broad range of organic cation substrates, xenobiotic compounds, various pharmaceutical drugs and toxins (13) . However, given its affinity for choline (~200 μM), it remains unlikely that organic cation transporters represent a major transport system. To that end, almost 20 years ago, complementation experiment in yeast made possible the discovery of the choline transporter-like protein family (CTL1-5) (14) . Since then, CTL1 has been the most thoroughly studied member of this family and is thought to play a vital role in the uptake of choline along the plasma membrane as well as the outer mitochondrial membrane (15) .
The CDP-choline and PEMT pathways have been thoroughly investigated. While early studies focused on hepatic choline uptake (16, 17) , how this process is regulated under normal and pathological conditions remains unclear. Here we show that in mouse primary hepatocytes, choline transport is mainly facilitated by an intermediate-affinity transport system, most likely CTL1. To mimic hepatocyte lipotoxicity observed during metabolic dysfunction, we report that the saturated fatty acid palmitate, but not oleate or a combination, diminished choline uptake and PC synthesis, which was associated with lower CTL1 transcript and protein, and independent of ER stress. Given that choline deficiency is intimately linked to the instigation and potentially the progression of fatty liver, endogenous regulation of choline uptake may serve as an important and regulated process.
EXPERIMENTAL PROCEDURES

Animals
C57Bl/6J mice (stock no. 00064) were originally purchased from Jackson Laboratories and maintained as a breeding colony at the University of Ottawa. Mice were exposed to a 12-h light/dark cycle (7:00am/7:00pm) and were fed ad libitum rodent diet (Envigo Teklad, 2018). Both male and female mice between 8 and 14 weeks were used for hepatocyte isolation. All of the experiments were performed with approval from the Animal Care Committee at the University of Ottawa.
Primary hepatocyte isolation
Primary hepatocytes were isolated via a collagenase perfusion as described previously (18) , but with slight modifications. Briefly, mice were anesthetized with a ketamine (150 mg/kg) and xylazine (10 mg/kg) mixture and livers were perfused through the inferior vena cava distal to the liver, with the vena cava clamped proximal to the liver and the portal vein cut. Livers were first perfused with 25 ml of an EGTA solution (140 mm NaCl, 6.7 mm KCl, 10 mm HEPES, and 50 μm EGTA, pH 7.4) and then 25 ml of a collagenase solution (67 mm NaCl, 6.7 mm KCl, 5 mm CaCl2·2H2O, and 100 mm HEPES, pH 7.6), both at a rate of 7 ml/min, using two syringe pumps with tubing connected via a Y-connector. Post perfusion, livers were removed and cells dissociated 6 manually in 10 ml of William's medium E (WME) (Wisent, 301-018-Cl) before passage through a 100 μm cell strainer. Cells were then pelleted, washed, resuspended in complete WME (10% fetal bovine serum (Wisent, 080150), 1% penicillin-streptomycin (Hyclone, SV30010) and 1% Glutamax (Fisher, 35050061) and plated 2x10 5 cells/ml for a 24-well plate, 4x10 5 cells/ml for a 12-well plate or 6x10 5 cells/ml for a 6-well plate. Plates were collagen-coated (Fisher, a1048301) prior to plating and cells were left to adhere for 4 h. Following, media was removed and cells were washed with PBS and complete WME and left overnight.
Fatty acid treatments
Hepatocytes were incubated for up to 48 h in bovine serum albumin (BSA)-conjugated FA. Briefly, sodium oleate (Sigma) and sodium palmitate (Sigma) were dissolved in 500 μl of 100% ethanol and heated to 65°C with occasional vortexing for 10 min. Endotoxin-free H2O was then added to a final volume of 1 ml, vortexed and aliquoted for storage at -20°C. Low-endotoxin BSA (Sigma; A8806) was added to complete WME (2%) and left to dissolve in a shaking bath. To conjugate, stock aliquots of FA were heated to 65°C and BSA-WME warmed to 37°C. FA solutions were added dropwise to BSA-WME and vortexed immediately. FA were conjugated to BSA for 2-3 h at 37°C. Control media contained 2% BSA with the appropriate amount of 50% ethanol, which served as the vehicle control for the FA treatments. Hepatocytes were treated with either BSAvehicle control, a mixture of palmitate and oleate (2:3, 0.5mM), palmitate (0.5 mM) or oleate (0.5 mM) for 48 h.
RNA Isolation, cDNA synthesis and qPCR
Total RNA was isolated using TriPure Reagent (Roche) as per the manufacturer's instructions.
Total RNA (up to 1 μg) was then reverse transcribed using the 5X All-In-One RT MasterMix (with AccuRT Genomic DNA Removal Kit) (ABM; G492), as per the kit's instructions. The resulting cDNA was diluted 1:20 with RNAse/DNase free H2O. Quantitate real-time PCR (qPCR) was performed using TaqMan primer/probe sets (Invitrogen) in combination with the QuantiNova Probe PCR Kit (Qiagen). Samples were run on the Rotor-Gene Q series (Qiagen). Relative expression was measured using the ΔΔ Ct method (19) and normalized to β actin and the ribosomal protein Rplp0.
Choline uptake
Following FA treatments, hepatocytes were incubated in Krebs-Ringer-HEPES buffer (KRH) (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, 10 mM glucose, pH 7.4) for 1 h prior to the uptake. The cells were then treated with [ 3 H]-choline (1 μCi/ml) in KRH for the indicated times. Following this, cells were washed 3 times to remove excess labeled choline, lysed in 0.1 M NaOH and snap frozen in liquid nitrogen. Cells were scraped and centrifuged at 14, 000 RPM for 10 min. An aliquot was used to determine radioactivity via liquid scintillation counting (LSC) using a Tri-Carb beta-scintillation counter (2910TR, Perkin Elmer). An aliquot was also used to determine protein content with a BCA Kit (Thermo Fisher Scientific).
Choline uptake inhibition
Following FA treatments, hepatocytes were incubated in KRH for 1 h. The cells were then treated with [ 3 H]-choline (1 μCi/ml) in KRH in the presence or absence the choline analog and uptake inhibitor hemicholinium-3 (HC3) (Sigma, H108-500MG) or the organic cation transporter inhibitor quinine (Tocris, 130-89-2), at the indicated concentrations. Both inhibitors were reconstituted in DMSO, which was added to the vehicle control experimental condition. [ 3 H]choline uptake was assessed after 10 min at 37°C as described above.
Choline uptake kinetics
Following FA treatments, hepatocytes were incubated in KRH for 1 h. The cells were then treated with [ 3 H]-choline (1 μCi/ml) in KRH in the presence of increasing concentrations of nonradiolabeled choline for 10 min at 37°C. Radioactivity and protein concentration were then determined as above. The initial rate of choline uptake was calculated using [(B x C) / (A x T)]/P, where A represented the total radioactivity subjected to the cell (DPM), B was the concentration of unlabeled choline (μM), C was the radioactivity in the sample (DPM), T was the uptake time (minutes) and P represents the amount of protein in the sample (mg).
Choline incorporation, lipid extraction and separation
Following FA treatments, hepatocytes were incubated for 4 h in WME containing either [ 3 H]choline (1 μCi/ml) or [ 14 C]-ethanolamine (0.1 μCi/ml). For estimates of phospholipid pool sizes, radiolabels were added at the time of FA treatment and left for 48 h. To determine the levels of PC degradation, following FA treatment, [ 3 H]-choline was added in WME for a period of 3 h, followed by a chase period from 1-4 h in an excess (100 μM) of unlabeled choline. Following these incubations, cells were then washed with PBS and lipids were extracted as previously described (20) . Briefly, hepatocytes were washed extensively with PBS, scraped in 200 μl of PBS on ice and 750 μl of chloroform/methanol (1:2, v/v) was added before a brief vortexing. Then, 250 μl of chloroform and 250 μl of dH2O was added; the samples were briefly vortexed and spun for 5 minutes at 3,000 RPM. The upper aqueous and lower organic lipid phases were separated and an aliquot taken for LSC. Alternatively, the lipid phase was removed and evaporated to dryness under a constant stream of nitrogen gas. Lipids were then resuspended in a small volume of chloroform prior to spotting on a thin layer chromatography (TLC) plate, where PC and PE were resolved in a solvent of chloroform/methanol/water (65:32:4, v/v/v). Phospholipid bands were visualized with iodine and scraped prior to LSC to determine radioactivity.
Western blots
A combination of denaturing and non-denaturing (no detergents or reducing agents) conditions were used for CTL1 western blots. Protein was equalized in non-denaturing lysis buffer (50 mM 
Lactate dehydrogenase viability assay
Cell viability was determined by measuring the levels of lactate dehydrogenase secreted in the media. Cell culture supernatant was collected and centrifuged at 12,000 RPM to pellet cell debris.
A 5 μl aliquot of media was added to a 96-well plate followed by the addition of 200 μl of a reaction buffer (NADH 0.2 mM and sodium pyruvate 2.5 mM in PBS). Wells were read immediately at 1 min intervals at 340 nm on a kinetic protocol for 10 min. The rate of change was proportional to the amount of lactate dehydrogenase in the media, and taken as a surrogate measure of viability.
Statistical analyses
All statistical analyses were completed using GraphPad Prism 7.03 (GraphPad Software Inc.).
Choline uptake saturation kinetic curves were generated using a non-linear regression, Michaelis-Menten curve fit, whereas choline uptake inhibition curves were generated using a logarithmic (inhibitor) vs. response curve fit. Comparison between two groups were made using a paired Student's t-test, whereas comparisons between more than two treatment groups were made using a one-way ANOVA analysis with a Tukey test for multiple comparisons, where significant differences relative to BSA or vehicle control are shown. All data are expressed as mean±SEM, unless specified in the figure legend.
RESULTS
Choline Transport in Primary Hepatocytes
While hepatic PC metabolism has been extensively studied in vitro and in vivo, there have been no studies addressing the first step of the CDP-choline pathway, choline transport, specifically in primary hepatocytes. Therefore, we first sought to define the characteristics of choline transport in (Figure 1 A) . Moreover, this choline transport activity was sensitive to the high-and intermediate-affinity choline uptake inhibitor HC3 (Figure 1 B) and unresponsive to specific inhibition of organic cation family transporters by quinine (Figure 1 C) , which has been shown effective at this dose in other cell culture systems.
Exogenous fatty acid treatment alters choline uptake
The liver is a dynamic metabolic organ that under normal, healthy conditions, functions to balance lipid synthesis, uptake and efflux. However, metabolic dysfunction associated with obesity and hepatic steatosis can result in a state of hepatocyte lipotoxicity (21) . To recapitulate this in vitro, we chronically (48 h) treated hepatocytes with a mixture of palmitate and oleate (2:3, 0.5 mM) that has been thought to be representative of the most abundant FA exposed to the liver in vivo, as well as palmitate and oleate in isolation, both at 0.5 mM. Following incubation, we observed a slight decrease in cell viability with FA treatments, which was more pronounced in the palmitatecontaining treatments, but still not statistically significant ( Figure S1 ). In response to FA treatment, the rate of choline uptake was diminished after FA treatment, with palmitate significantly inhibiting the rate of choline uptake in comparison with BSA-vehicle treated cells (Figure 2 ).
Since hepatocyte choline uptake was shown to be facilitated mainly by intermediate-affinity (CTL1-mediated) transport, we next looked to measure the transcript and protein expression of the main choline transporters in hepatocytes. In response to both palmitate and oleate, but not the combination mixture, Slc44a1 transcript expression was significantly lower compared to BSA control-treated cells (Figure 3 A) . This trend was also observed at the protein level, where upon all FA treatments, CTL1 protein content was significantly diminished (Figure 3 B) , which aligned well with the lower rate of choline uptake observed in FA-treated cells (Figure 2 ). While CTL1 has been implicated as the main choline transporter, CTL2 was also expressed in the liver and was significantly down regulated at the transcript level in response to palmitate (Figure 3 Choline uptake is the initial step in the CDP-choline pathway, where once internalized, choline destined for phospholipid synthesis is thought to be immediately phosphorylated by CHKα, shuttled to CCT and finally incorporated into PC by choline/ethanolamine phosphotransferase (CEPT). Although various FA reduced choline uptake and the expression of CTL1 protein, only palmitate treatment down regulated the expressions of Chkα and Cept, with no transcriptional changes in Pcyt1a (Figure 4 A-C) , similar to the regulatory gene in the CDP-ethanolamine pathway, Pcyt2 ( Figure S2 ). In addition to the CDP-choline pathway, the liver can convert PE to PC via the PE methylation pathway. While it is known that PEMT activity in primary hepatocytes diminishes greatly after culturing (22) , we observed a slight, but statistically significant increase in the expression of Pemt with palmitate treatment (Figure 4 D) . Therefore, while chronic palmitate/oleate-or oleate-treated hepatocytes experience decrease in CTL1 protein content, palmitate-treatment had a more global effect on the expression of choline transport, CDP-choline pathway and PE methylation genes.
Palmitate treatment lowers CDP-choline PC synthesis and degradation
To investigate the significance of altered choline uptake, we measured the incorporation of [ 3 H]choline into PC after the 48 h FA treatment. In a 4 h pulse experiment, we observed a significant reduction in labeled choline incorporation into PC (Figure 5 A) , entirely consistent with the reduced choline uptake (Figure 2 ). To assess the total pool of PC, we monitored the incorporation of [ 3 H]-choline into PC over the duration of the 48 h FA treatment, after which the labeled choline is anticipated to reach an equilibrium and represent steady-state levels of PC (18, 23) . Interestingly, we saw no difference between any of the FA treatments compared to BSA control-treated cells (Figure 5 B) . Given the apparent difference in PC synthesis via the CDP-choline pathway and the constant levels of PC, we next investigated the rate of PC degradation via pulse-chase. After chronic FA treatment, palmitate/oleate or oleate had no effect. However, palmitate treatment significantly impaired the rate at which PC was degraded, likely contributing to its maintained levels (Figure 5 C) .
Palmitate treatment does not alter the CDP-ethanolamine or PEMT pathway
Given that reductions in choline uptake observed with FA (mainly palmitate) treatment altered PC synthesis, we next assessed whether chronic lipid loading of hepatocytes altered the incorporation of ethanolamine into PE. While there was no change between conditions in the short-term incorporation of labeled ethanolamine into PE (Figure 6 A) , palmitate/oleate and palmitate reduced total levels of PE, compared to BSA control-treated cells (Figure 6 B) . Finally, to test the role of PE methylation under these conditions, we attempted to measure the amount of [ 14 C]-ethanolamine incorporated into PE and then converted to PC during a 4 h labeling period following the FA treatment. However, we were unable to measure any radioactivity in PC after [ 14 C]-ethanolamine pulse (data not shown), which is consistent with previous reports that PEMT activity dramatically decreases after hepatocytes are cultured for more than 24 h (22) . To have an indication as to the partial contribution of the PEMT pathway in these cells, we performed chronic labeling experiments, where cells were co-incubated with FA as well as [ 14 C]-ethanolamine for 48 h. Under these conditions, we observed no difference in PEMT-derived PC between any of the FA treatments, compared to BSA control-treated cells (Figure 6 C) .
ER stress is not responsible for FA-induced reductions in choline uptake
It is well documented that hepatic exposure to high and chronic levels of saturated FA leads to ER stress leading to metabolic dysfunction and induction of cell death pathways (21) . We reasoned that palmitate-induced reductions in choline uptake, CTL1 and choline incorporation into PC might be due to palmitate-induced ER stress. To test this, we used the well-known inducer of ER stress, tunicamycin (24) , which significantly affected cell viability ( Figure S3 ). Contrary to our hypothesis, while FA-treatment inhibited choline uptake, induction of ER stress resulted in a dosedependent increase in choline transport (Figure 7 A) . This was accompanied by significant increases in choline transporter (Slc44a1, Slc44a2 and Slc22a1) transcript expressions (Figure 7 B-D). However, despite validation of ER stress using known markers, CTL1 and CTL2 protein content were not changed compared to vehicle control (Figure 7 E) .
ER stress leads to marked reduction in CDP-choline PC flux
Since we observed that tunicamycin-induced ER stress augmented choline uptake, we anticipated that the incorporation of choline into PC would follow suit. However, we saw a dramatic reduction in the 4 h incorporation of labeled choline into PC (Figure 8 A) . When we incubated tunicamycintreated cells concurrently with [ 3 H]-choline or [ 14 C]-ethanolamine for 48 h to estimate total PC and PE, respectively, there was a dose dependent decrease in the total levels of both phospholipids as generated by the CDP-choline (Figure 8 B) and CDP-ethanolamine pathways (Figure 8 C) , with no net change in PEMT-derived PC (Figure 8 D) . Interestingly, the transcript expression of CDPcholine and CDP-ethanolamine pathway genes were increased at the lower dose of tunicamycin, compared to vehicle control (Figure 9 A-D) . There was no difference in the expression of Pemt (Figure 9 E) .
DISCUSSION
Choline is an essential nutrient that needs to be obtained from dietary sources to supplement low levels of endogenous synthesis. The liver is one of the main sites of choline metabolism, since it has the capacity for both PC synthesis, as well as mitochondrial oxidation, the first and irreversible step toward its incorporation as a methyl donor. Via its integration into PC, hepatic choline availability governs many aspects of hepatic phospholipid metabolism, such as triglyceride synthesis and VLDL formation (3, 25) . While there has been a concerted effort to map the fate of hepatic choline once inside the cell, there have been few reports that have aimed to characterize the specific transport of choline under normal or pathological conditions.
Here, we report that in primary murine hepatocytes, choline is transported via an intermediateaffinity system that is consistent with the choline transporter-like family of proteins, of which CTL1 and CTL2 represent the most likely candidates. While there have been other reports that have characterized choline transporters in various immortalized cell lines (12) , many of which are cancer-derived, very little focus has been given to understanding choline transport in primary cells.
Moreover, while we demonstrate evidence for the CTL1-5 family as being the main facilitators of choline uptake, the relative contribution of each protein remains unknown. Past studies have used siRNA and antibody occlusion to tease out a primary role for CTL1 in macrophage biology (26, 27) ; however, the nature of primary hepatocytes and the lack of validated primary antibodies for all transporters make this approach difficult. In the future, it will be important to assess the relative contribution of at least the main transporters, Slc44a1 and Slc44a2 in genetic loss-of-function models.
It is well known that altering choline availability or hepatic choline metabolism drives patterns of altered lipid homeostasis (10, (28) (29) (30) (31) (32) (33) (34) (35) . Early studies by Charles Best and others documented that liver dysfunction associated with choline deficiency was reversed by choline supplementation via delivery of PC (4) (5) (6) . Moreover, while considered a dramatic model, choline and methionine deficiency very rapidly induces hepatic steatosis that has some of the key hallmarks of human nonalcoholic fatty liver disease (36) . However, given the continuing rise in the rates of obesity and fatty liver disease, we considered that choline uptake as an initiator of choline incorporation into PC via the CDP-choline pathway might be affected by the onset of hepatic lipid accumulation. To model this in vitro, we treated isolated primary hepatocytes with a mixture or individual FA that are well documented to both mirror circulating FA profiles during obesity (37) , as well as mimic the increased lipid burden in hepatocytes (38) . While FA treatment induced a certain level of cellular stress as expected, cell viability as judged by the release of lactate dehydrogenase into the media was not significantly increased in FA-treated cells ( Figure S1 ). Previous reports have documented a more dramatic effect on markers of cell death and viability with palmitate treatment, at or above the amount used in our study (0.5 mM) and for less duration (39, 40) ; however, in our study, it does not appear as though the FA-induced reductions in choline uptake are due to diminished cell viability.
While our results demonstrate that in hepatocytes chronically treated (48 h) with FA, choline uptake tended to be decreased independent of the type of lipid, palmitate alone had the clearest inhibition ( Figure 2 ). This was associated with a reduction in total protein content of CTL1.
Although it has been shown that mechanistic target of rapamycin complex (mTORC1) is able to control PC levels via translational regulation of CCTα (41), the decrease in CTL1 protein can likely be explained by a similar decrease in transcript levels. It is interesting to note that the levels of Slc44a1 are not significantly diminished after only 24 h of FA treatment (data not shown), which suggests that the transcriptional repression is happening on a more chronic scale. The expression of other choline transporters and CDP-choline pathway genes were also lower with palmitate; however, protein levels were not assessed. Moreover, independent of these down-regulated genes and lower CTL1 protein content, measures of total PC were not different between any of the treatments. We observed that the degradation of PC was significantly reduced in palmitate-treated cells compared to control, which is a surrogate measure for phospholipase D activity ( Figure 5C ).
We reasoned it possible that reductions in choline uptake were caused by the reduced expression of CTL1, but that degradation was diminished to account for the lower amount of PC produced, similar to adaptations that occur when the CDP-ethanolamine pathway is diminished (42).
However, it remains possible that 1) PC synthesis is normal and differences in choline transport mask this effect with radiolabeling, and 2) that similar to choline deficiency in hepatocytes, the availability of phosphocholine (the product of CHKα) is sufficiently above the Km of CCTα, such that the levels of choline converted to phosphocholine were never limiting (43) . Moreover, future work involving specific knockdown of Slc44a1 will be necessary to ascribe the effect completely on its down-regulation.
Previous links have been made between FA-induced changes and choline metabolism. In the immortalized mouse myoblast C2C12 cell line, palmitate was shown to limit cellular choline uptake, which was associated with increased lysosomal degradation of CTL1, whereas oleate was seen to decrease only mitochondrial choline uptake, but stimulate PC synthesis overall (44) . In our hepatocyte experiments, we observed that palmitate, but not oleate lowered Slc44a1 transcript expression, which resulted in an overall reduction of CTL1 protein. We did not evaluate mitochondrial localization of CTL1, nor did we evaluate the fate of oxidized choline, which occurs in the mitochondria in liver cells. Therefore, it is possible that in hepatocytes, there are effects of SFA and MUFA that are going unreported. Recently, in Pcyt1a-deficient macrophages, a decreased rate of PC turnover facilitated a shift toward more polyunsaturated FA in membrane phospholipids, which stemmed their inflammatory potential (45) . While our study was focused on the consequence of exogenous FA treatment on choline transport and subsequent metabolism, 1) that PC metabolism can be regulated because of pathway interruptions is in keeping with our results and 2) it is possible that alterations in phospholipid FA composition might alter the membrane properties that can affect transport proteins (46) . Finally, many studies have now linked phospholipid biosynthetic pathways with diacylglycerol and triglyceride synthesis, storage and metabolism (10, 18, 23, 27, 33, (47) (48) (49) . There remains the possibility that exogenous FA might feedback to affect choline metabolism via neutral lipid homeostasis; however, this was not addressed here.
Given that palmitate-induced changes on choline metabolism were consistently the most apparent, we hypothesized that ER stress may be the root cause of this effect. However, when we used the well-known ER stress-inducing agent tunicamycin (24) , choline uptake, counter to our expectations, increased. This was associated with a consistent increase in the transcript expression of choline transporters with no change in the total levels of CTL1 or CTL2 protein. It remains entirely possible that rather than an increase in protein content, the distribution of CTL1 (or other transporters) shifted from intracellular to membrane, thus facilitating the increase in choline uptake.
In spite of there being an increase in the acute uptake of choline, the incorporation of choline and ethanolamine into their respective phospholipids was greatly diminished and was not compensated by increases in PEMT protein amounts. This was also independent of a general increase in the gene expression of many CDP-choline and CDP-ethanolamine pathways transcripts, though it might be that translation of these transcripts was generally suppressed given the level of ER dysfunction. Since ER homeostasis is critical for phospholipid biosynthetic enzymes, this was perhaps not surprising (50) . Therefore, although palmitate is well known for inducing ER stress, a separate and yet unknown mechanism is responsible for diminishing choline uptake in hepatocytes.
In conclusion, we show for the first time in primary hepatocytes that choline is primarily taken into the cell via intermediate affinity transporters and that in response to exogenous FA, choline transport and PC synthesis is suppressed. However, total PC levels are maintained via a reduction in PC turnover. Finally, FA-induced disruption to choline transport was not mediated by the induction of ER stress. Our results suggest that the metabolism (uptake, synthesis and degradation) of choline and PC might be altered in pathological states of obesity and/or non-alcoholic fatty liver disease. 
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